ArticleAmerican journal of translational research2025
Efficacy of ACTH therapy in treating infantile epileptic spasm syndrome and its effect on Kramer score.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the clinical efficacy and safety of adrenocorticotropic hormone (ACTH) combined with topiramate versus topiramate monotherapy in treating Infantile Epileptic Spasm Syndrome (IESS), and to explore the risk factors for relapse.
methodsThis retrospective cohort study included 185 IESS pediatric patients treated at Yan'an People's Hospital between April 2018 and January 2024. Patients were divided into a control group (n=95, topiramate monotherapy) and an observation group (n=90, ACTH combined with topiramate) based on their treatment regimen. Propensity score matching (PSM) was employed to balance baseline differences. Outcomes compared between the groups included spasm control rates, electroencephalogram (EEG) improvement, changes in functional scores, and incidence of adverse reaction. Multivariate logistic regression was used to identify independent risk factors for relapses.
resultsThe observation group demonstrated significantly higher rates of complete spasm control (75.56% vs. 50.53%) and complete EEG improvement (76.67% vs. 54.74%) compared to the control group (P<0.01). Post-treatment, the observation group showed more significant improvements in developmental quotient (DQ), motor index (MI), and Kramer scores (P<0.01). Multivariate analysis identified structural etiology (OR=3.12), monotherapy (OR=2.54), and higher Kramer scores (OR=1.45) as independent risk factors for relapse (all P<0.01). The incidence of adverse reactions did not differ significantly between groups (34.44% vs. 29.47%, P=0.468).
conclusionACTH combined with topiramate offers superior efficacy for spasm control, EEG improvement, and neurological function recovery compared to topiramate monotherapy, without increasing adverse reactions. Structural etiology, monotherapy, and Kramer scores are independent predictors for relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.